DE69215568D1 - Verfahren zur Hemmung der Sauerstofftoxizität in den Lungen - Google Patents

Verfahren zur Hemmung der Sauerstofftoxizität in den Lungen

Info

Publication number
DE69215568D1
DE69215568D1 DE69215568T DE69215568T DE69215568D1 DE 69215568 D1 DE69215568 D1 DE 69215568D1 DE 69215568 T DE69215568 T DE 69215568T DE 69215568 T DE69215568 T DE 69215568T DE 69215568 D1 DE69215568 D1 DE 69215568D1
Authority
DE
Germany
Prior art keywords
lungs
oxygen toxicity
inhibiting oxygen
inhibiting
toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69215568T
Other languages
English (en)
Other versions
DE69215568T2 (de
Inventor
Craig D Wegner
L Gordon Letts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOEHRINGER INGELHEIM PHARMACEUTICALS Inc RIDGEFIELD CONN US
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
BOEHRINGER INGELHEIM PHARMACEUTICALS Inc RIDGEFIELD CONN US
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOEHRINGER INGELHEIM PHARMACEUTICALS Inc RIDGEFIELD CONN US, Boehringer Ingelheim Pharmaceuticals Inc filed Critical BOEHRINGER INGELHEIM PHARMACEUTICALS Inc RIDGEFIELD CONN US
Publication of DE69215568D1 publication Critical patent/DE69215568D1/de
Application granted granted Critical
Publication of DE69215568T2 publication Critical patent/DE69215568T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69215568T 1991-04-03 1992-03-24 Verfahren zur Hemmung der Sauerstofftoxizität in den Lungen Expired - Lifetime DE69215568T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67987091A 1991-04-03 1991-04-03

Publications (2)

Publication Number Publication Date
DE69215568D1 true DE69215568D1 (de) 1997-01-16
DE69215568T2 DE69215568T2 (de) 1997-05-15

Family

ID=24728710

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69215568T Expired - Lifetime DE69215568T2 (de) 1991-04-03 1992-03-24 Verfahren zur Hemmung der Sauerstofftoxizität in den Lungen

Country Status (13)

Country Link
US (1) US5310551A (de)
EP (1) EP0507187B1 (de)
JP (1) JP3228548B2 (de)
AT (1) ATE145827T1 (de)
AU (1) AU655459B2 (de)
CA (1) CA2064604C (de)
DE (1) DE69215568T2 (de)
DK (1) DK0507187T3 (de)
ES (1) ES2094837T3 (de)
GR (1) GR3022578T3 (de)
HK (1) HK1003106A1 (de)
NZ (1) NZ242192A (de)
ZA (1) ZA922408B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
WO2019191128A1 (en) * 2018-03-26 2019-10-03 The United States Of America As Represented By The Secretary Of The Navy Use of tiotropium bromide to prevent pulmonary oxygen toxicity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
ES2035668T3 (es) * 1989-03-09 1993-04-16 Boehringer Ingelheim Pharmaceuticals Inc. Uso de moleculas de adherencia intercelular y sus ligandos de union en el tratamiento del asma.

Also Published As

Publication number Publication date
DK0507187T3 (da) 1997-04-07
ATE145827T1 (de) 1996-12-15
ZA922408B (en) 1992-12-30
EP0507187B1 (de) 1996-12-04
AU655459B2 (en) 1994-12-22
US5310551A (en) 1994-05-10
CA2064604A1 (en) 1992-10-04
HK1003106A1 (en) 1998-10-09
JPH05255103A (ja) 1993-10-05
NZ242192A (en) 1997-06-24
EP0507187A1 (de) 1992-10-07
AU1398692A (en) 1992-10-08
ES2094837T3 (es) 1997-02-01
JP3228548B2 (ja) 2001-11-12
DE69215568T2 (de) 1997-05-15
GR3022578T3 (en) 1997-05-31
CA2064604C (en) 2007-07-10

Similar Documents

Publication Publication Date Title
DE69232480D1 (de) Beatmungsgerät zur Erzeugung von kontinuierlichem positiven Atemwegdruck (CPAP)
FI954092A0 (fi) Menetelmä hengityslaitteen ohjaamiseksi uniapnean hoidossa
DE69422900T2 (de) Vorrichtung zur Erzeugung eines kontinuierlichen positiven Atemwegdruckes (CPAP)
ATA43692A (de) Verfahren zur herstellung eines konzentrates von standardisiertem, menschlichem von willebrand-faktor
DE59201882D1 (de) Verfahren zur Erkennung der Atemphasen eines Patienten bei assistierenden Beatmungsverfahren.
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DK0606351T3 (da) Apparat til sikring af lungetilstanden
SE9801427D0 (sv) Förfarande för bestämning av minst en parameter samt en andningsapparat
SE9402237D0 (sv) Measurement methods and systems
DE3784693T2 (de) Verwendung von fluticasonpropionat zur herstellung eines praeparats zur behandlung von darmerkrankungen.
FI95873B (fi) Inhalaatiolaitteen yhteydessä käytettävä venttiili
ATE143260T1 (de) Verwendung von (s)-isofluran und (s)-desfluran zur anästhesie sowie entsprechende arzneimittelzubereitungen
DK0699414T3 (da) Anlæg til sygdomsbehandling
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE69215568T2 (de) Verfahren zur Hemmung der Sauerstofftoxizität in den Lungen
DE69325452D1 (de) Verfahren zur herstellung von (s)-3-amino-1-substituiert-pirrolidine
ATE162218T1 (de) Verfahren zur herstellung eines virussicheren thrombinkonzentrates
ATE121420T1 (de) Verfahren zur herstellung von 3-(l-pyroglutamyl)- l-thiazolidin-4-carbonsäure-derivaten.
DE59105327D1 (de) Verfahren zur Herstellung eines Feuchthaltemittels.
SE8903764L (sv) Lung protection agents
ATE258926T1 (de) Verfahren zur herstellung von ranitidin
DE59408965D1 (de) Verfahren zur Herstellung langzeitstabiler klarer Seren
DE69402241T2 (de) Verwendung von 2-Acetylpyridine zur Herstellung eines Arzneimittles zur Unterdrückung des Rauchens
DE69202238T2 (de) Neue naphthalinderivate und verfahren zur herstellung.
DK0609471T3 (da) Anvendelse af kollagen til behandling af sygelige ledprocesser

Legal Events

Date Code Title Description
8364 No opposition during term of opposition